Andrew Pettitt

Dec 11, 2023 | nejm.org | David Cairns |David J. Allsup |Kate Cwynarski |Andrew Pettitt

December 10, 2023 DOI: 10.1056/NEJMoa2310063 AbstractThe combination of ibrutinib and venetoclax has been shown to improve outcomes in patients with chronic lymphocytic leukemia (CLL) as compared with chemoimmunotherapy. Whether ibrutinib–venetoclax and personalization of treatment duration according to measurable residual disease (MRD) is more effective than fludarabine–cyclophosphamide–rituximab (FCR) is unclear.